GFM
RARE icon

GF Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

GF Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.4K Buy
2,166
+271
+14% +$6.1K ﹤0.01% 412
2025
Q4 		$43.6K Sell
1,895
-178
-9% -$5.85K ﹤0.01% 417
2025
Q3 		$62.4K Sell
2,073
-291
-12% -$8.73K ﹤0.01% 373
2025
Q2 		$86K Hold
2,364
– – ﹤0.01% 379
2025
Q1 		$85.6K Buy
2,364
+425
+22% +$17.7K ﹤0.01% 375
2024
Q4 		$81.6K Buy
+1,939
New +$96.2K ﹤0.01% 347

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

GF Fund Management's RARE Position: Q1 2026 in Review

GF Fund Management increased its Ultragenyx Pharmaceutical (RARE) stake by 14% in Q1 2026, buying an estimated $6.1K and bringing the position to 2,166 shares worth $45.4K. The position accounts for ﹤0.01% of the portfolio, ranked #412.

GF Fund Management first reported a position in RARE in Q4 2024 and has held it in 6 quarters since. The position peaked at $86K in Q2 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • GF Fund Management held 2,166 shares of Ultragenyx Pharmaceutical worth $45.4K as of Q1 2026.
  • GF Fund Management bought 271 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $6.1K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #412 holding.
  • GF Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Ultragenyx Pharmaceutical position peaked at $86K in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.